Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

Bente Glintborg; Mikkel Østergaard; Niels Steen Krogh; Ulrik Tarp; Natalia Manilo; Anne Gitte Rasmussen Loft; Annette Hansen; Annette Schlemmer; Victoria Fana; Hanne M Lindegaard; Henrik Nordin; Claus Rasmussen; Leif Ejstrup; Dorte Vendelbo Jensen; Peter Mosborg Petersen; Merete Lund Hetland

doi:10.1136/annrheumdis-2012-201933

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh, Ulrik Tarp, Natalia Manilo, Anne Gitte Rasmussen Loft, Annette Hansen, Annette Schlemmer, Victoria Fana, Hanne M Lindegaard, Henrik Nordin, Claus Rasmussen, Leif Ejstrup, Dorte Vendelbo Jensen, Peter Mosborg Petersen, Merete Lund Hetland

Research output: Contribution to journal › Journal article › Research › peer-review

120 Citations (Scopus)

Abstract

To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care.

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	72
Issue number	7
Pages (from-to)	1149-55
Number of pages	7
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2012-201933
Publication status	Published - Jul 2013

Keywords

Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Denmark
Drug Substitution
Female
Humans
Immunoglobulin G
Male
Medication Adherence
Middle Aged
Pain Measurement
Receptors, Tumor Necrosis Factor
Registries
Spondylitis, Ankylosing
Treatment Outcome
Tumor Necrosis Factor-alpha

Access to Document

10.1136/annrheumdis-2012-201933

AUB Link

Search for the material in Aalborg University Library's search engine

Fingerprint

Dive into the research topics of 'Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry'. Together they form a unique fingerprint.

Cite this

Glintborg, B., Østergaard, M., Krogh, N. S., Tarp, U., Manilo, N., Loft, A. G. R., Hansen, A., Schlemmer, A., Fana, V., Lindegaard, H. M., Nordin, H., Rasmussen, C., Ejstrup, L., Jensen, D. V., Petersen, P. M., & Hetland, M. L. (2013). Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases, 72(7), 1149-55. https://doi.org/10.1136/annrheumdis-2012-201933

@article{322faf95329a4634b4f1d9e2db3f9739,

title = "Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry",

abstract = "To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care.",

keywords = "Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Denmark, Drug Substitution, Female, Humans, Immunoglobulin G, Male, Medication Adherence, Middle Aged, Pain Measurement, Receptors, Tumor Necrosis Factor, Registries, Spondylitis, Ankylosing, Treatment Outcome, Tumor Necrosis Factor-alpha",

author = "Bente Glintborg and Mikkel {\O}stergaard and Krogh, {Niels Steen} and Ulrik Tarp and Natalia Manilo and Loft, {Anne Gitte Rasmussen} and Annette Hansen and Annette Schlemmer and Victoria Fana and Lindegaard, {Hanne M} and Henrik Nordin and Claus Rasmussen and Leif Ejstrup and Jensen, {Dorte Vendelbo} and Petersen, {Peter Mosborg} and Hetland, {Merete Lund}",

year = "2013",

month = jul,

doi = "10.1136/annrheumdis-2012-201933",

language = "English",

volume = "72",

pages = "1149--55",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "7",

}

Glintborg, B, Østergaard, M, Krogh, NS, Tarp, U, Manilo, N, Loft, AGR, Hansen, A, Schlemmer, A, Fana, V, Lindegaard, HM, Nordin, H, Rasmussen, C, Ejstrup, L, Jensen, DV, Petersen, PM & Hetland, ML 2013, 'Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry', Annals of the Rheumatic Diseases, vol. 72, no. 7, pp. 1149-55. https://doi.org/10.1136/annrheumdis-2012-201933

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. / Glintborg, Bente; Østergaard, Mikkel; Krogh, Niels Steen et al.
In: Annals of the Rheumatic Diseases, Vol. 72, No. 7, 07.2013, p. 1149-55.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy

T2 - results from the Danish nationwide DANBIO registry

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Krogh, Niels Steen

AU - Tarp, Ulrik

AU - Manilo, Natalia

AU - Loft, Anne Gitte Rasmussen

AU - Hansen, Annette

AU - Schlemmer, Annette

AU - Fana, Victoria

AU - Lindegaard, Hanne M

AU - Nordin, Henrik

AU - Rasmussen, Claus

AU - Ejstrup, Leif

AU - Jensen, Dorte Vendelbo

AU - Petersen, Peter Mosborg

AU - Hetland, Merete Lund

PY - 2013/7

Y1 - 2013/7

N2 - To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care.

AB - To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care.

KW - Adult

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antirheumatic Agents

KW - Denmark

KW - Drug Substitution

KW - Female

KW - Humans

KW - Immunoglobulin G

KW - Male

KW - Medication Adherence

KW - Middle Aged

KW - Pain Measurement

KW - Receptors, Tumor Necrosis Factor

KW - Registries

KW - Spondylitis, Ankylosing

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

U2 - 10.1136/annrheumdis-2012-201933

DO - 10.1136/annrheumdis-2012-201933

M3 - Journal article

C2 - 22941767

SN - 0003-4967

VL - 72

SP - 1149

EP - 1155

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 7

ER -

Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AGR et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases. 2013 Jul;72(7):1149-55. doi: 10.1136/annrheumdis-2012-201933